Hormonal
Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) and GLP-1 receptor agonists (e.g., semaglutide) induce significant weight loss and improve glycemic control in patients with type 2 diabetes and obesity by acting on central satiety centers and peripheral metabolic pathways.
If you have T2DM or obesity, GLP-1 and dual GIP/GLP-1 agonists are highly effective treatments that work by mimicking natural gut hormones to reduce appetite and improve blood sugar. They are available as weekly injections or daily oral pills. Consult your doctor to see if one of these FDA-approved medications is right for you.
Several GLP-1 and dual GIP/GLP-1 receptor agonists have been developed to harness these pharmacological effects in the treatment of type 2 diabetes, with some demonstrating robust effectiveness in weight management and prevention of cardiovascular diseases.
Why this rating
The paper cites multiple FDA-approved agents, phase 1-3 clinical trials, and extensive preclinical data.
Source
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Qiyuan Keith Liu · Frontiers in Endocrinology · 2024
DOI 10.3389/fendo.2024.1431292
More from this paper
- GLP-1 receptor agonists delay gastric emptying, which reduces postprandial lipid and carbohydrate surges and contributes to satiety.Strong
- GIP promotes lipogenesis (fat storage) in adipose tissue, while GLP-1 promotes lipolysis (fat breakdown) indirectly via sympathetic nervous system activation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →